Ola Brodin
- Oncology top 2%
- Pulmonary and Respiratory Medicine top 2%
- Epidemiology top 5%
- Molecular Biology
- Cancer Research top 10%
- Co-authors
- Michael C. PerryJean‐Pierre PignonB LebeauR JossR. ArriagadaDavid H. JohnsonHenry WagnerT Onoshi
- Topics
- Lung Cancer Research Studies (16 papers)Lung Cancer Treatments and Mutations (15 papers)Lung Cancer Diagnosis and Treatment (7 papers)
- Partner nations
- SwedenDenmarkUnited Kingdom
In The Last Decade
Ola Brodin
63 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 117
- Oncology 1.4k
- Pulmonary and Respiratory Medicine 861
- Epidemiology 799
- Molecular Biology 671
- Cancer Research 197
Countries citing papers authored by Ola Brodin
This map shows the geographic impact of Ola Brodin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ola Brodin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ola Brodin more than expected).
Fields of papers citing papers by Ola Brodin
This network shows the impact of papers produced by Ola Brodin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ola Brodin. The network helps show where Ola Brodin may publish in the future.
Co-authorship network of co-authors of Ola Brodin
This figure shows the co-authorship network connecting the top 25 collaborators of Ola Brodin. A scholar is included among the top collaborators of Ola Brodin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ola Brodin. Ola Brodin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 7 | |
| 3 | 9 | |
| 4 | Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group | 1 |
| 5 | 11 | |
| 6 | 41 | |
| 7 | 17 | |
| 8 | 39 | |
| 9 | 8 | |
| 10 | 55 | |
| 11 | 18 | |
| 12 | 22 | |
| 13 | 18 | |
| 14 | Basic fibroblast growth factor and vascular fibroblast growth factor measured in sera from patients with non-small cell lung cancer. | 3 |
| 15 | 32 | |
| 16 | 43 | |
| 17 | 57 | |
| 18 | 55 | |
| 19 | 24 | |
| 20 | 15 |
About Ola Brodin
Ola Brodin is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine, having authored 65 papers that have together received 2.2k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (16 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Diagnosis and Treatment (7 papers). The work is most often cited by research in Oncology (1.4k citations), Pulmonary and Respiratory Medicine (861 citations) and Epidemiology (799 citations). Ola Brodin has collaborated with scholars based in Sweden, Denmark and United Kingdom. Frequent co-authors include Michael C. Perry, Jean‐Pierre Pignon, B Lebeau, R Joss, R. Arriagada, David H. Johnson, Henry Wagner, T Onoshi, Martin H.N. Tattersall and Merrill S. Kies. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.